کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
5528065 | 1547913 | 2017 | 6 صفحه PDF | دانلود رایگان |
- This is a systematic review of aspirin use on the incidence risk of multiple myeloma.
- There is no evidence that aspirin modifies the risk of multiple myeloma.
- More studies are needed to assess the impact of aspirin on the risk of multiple myeloma.
Multiple myeloma is a relatively uncommon plasma cell malignancy. Preclinical and clinical studies have suggested that aspirin might modify the risk of multiple myeloma. We performed a systematic review and meta-analysis of studies to examine the association between regular aspirin use and risk of multiple myeloma. Five observational studies including 332,660 adults were evaluated. The pooled estimate had a hazard ratio of 0.90 (95% confidence interval =0.58â1.39; P=0.638). Odds ratios from the two case-control studies were similar. The findings demonstrated that there was no significant association between aspirin use and the risk of multiple myeloma.
Journal: Leukemia Research Reports - Volume 7, 2017, Pages 23-28